Clinical impact of mucus plugs in bronchiectasis
Mucus plugs in bronchiectasis and respiratory symptoms
We aimed to determine whether the presence of mucus plugs (MP) is associated with worse respiratory symptoms and whether MP extent correlates with symptom severity.
Assessment of mucus plugs in 133 adults
We conducted a cross-sectional study including 133 adults with clinically and radiologically confirmed bronchiectasis attending a specialist outpatient clinic.
Mucus plugs and symptom severity
MP were identified in 88 patients (66%). Compared with those without MP, patients with MP had significantly worse QoL-B RSS (median 77.8 vs. 83.3; p = 0.01) and higher CAAT scores (10.0 vs. 7.0; p = 0.04).
Mucus plugging as a potential imaging marker
Mucus plugging is associated with worse respiratory symptoms and chronic Pseudomonas aeruginosa infection and may represent a clinically relevant imaging marker of disease activity in bronchiectasis.
Authors
Alessandro De Angelis, Lidia Perea, Pau Marrades, Alessandra Iorfida, Nuria Mendoza, Rosanel Amaro, Pilar Martinez-Olondris, Jin-Seok You, Elena Rodriguez-Lobato, Mariana Benegas, Marcelo Sanchez, Antonio Voza, Alvar Agusti, Rosa Faner, James D. Chalmers, Stefano Aliberti, Oriol Sibila
Read more details at
Fecha de publicación
01 July 2026
Categorías asociadas al artículo
Noticias relacionadas
Año SEPAR de la Vía Aérea 2026/27: una iniciativa para mejorar la salud respiratoria
Descubre el Año SEPAR de la Vía Aérea 2026/27 y sigue sus contenidos sobre asma, EPOC y bronquiectasias para mejorar la salud respiratoria.
Clinical, molecular and microbial characterisation of the eosinophilic endotype of bronchiectasis: data from the EMBARC-BRIDGE study
Analysis of eosinophilic bronchiectasis exploring airway inflammation, blood eosinophils, microbial associations and disease severity using LC-MS/MS techniques.
Bronchiectasis and treatable traits: the journey from concept to clinical practice
Review of the treatable traits approach in bronchiectasis, exploring phenotypes, endotypes, comorbidities, and its translation into clinical practice.
Systemic Immune Dysregulation in Patients With Bronchiectasis and Chronic Pseudomonas aeruginosa Infection
Study reveals systemic immune alterations in bronchiectasis patients with chronic Pseudomonas infection, highlighting persistent immune imbalance.
Symptoms, risk of future exacerbations, and response to long-term macrolide treatment in bronchiectasis: an observational study
Observational study shows bronchiectasis symptoms independently predict exacerbations and identify patients who benefit from macrolide therapy, even with few prior episodes.
A Bispecific Monoclonal Antibody Targeting Psl and PcrV for Chronic Pseudomonas Aeruginosa Infection in Patients With Bronchiectasis: Results From a Randomized, Double-Blind Placebo-Controlled Trial (GREAT-2)
The GREAT-2 trial shows that gremubamab significantly reduces Pseudomonas aeruginosa load and enhances quality of life in bronchiectasis patients. Discover the results now.
Imagen desarrollada con ChatGPT